Anglo-Swedish drug major AstraZeneca and US drug developer Targacept say that top-line results from a Phase IIb trial of AZD3480 in cognitive dysfunction in schizophrenia were disappointing and do not warrant progressing the agent into late-stage testing.
The HALO trial showed that AZD3480 did not meet the criteria for statistical significance on the primary endpoints, improvement on various cognitive domains measured by the IntegNeuro computerized test battery. AZD3480 was generally well tolerated, they noted.
In addition to the HALO study, the firms have also previously reported top-line data from a Phase IIb trial of AZD3480 in mild-to-moderate Alzheimer's disease and are currently evaluating the agent in a Phase II exploratory study in attention-deficit hyperactivity disorder in adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze